Views
5 years ago

109 - E Carranza Vélez- Junio 2018

  • Text
  • Ii
  • Etifoxina
  • Antidepresivos
  • Afectivos
  • Neuroactivos
  • Allo
  • Allopregnenolona
  • Velez
  • Tspo
  • Clozapina
  • Corteza
  • Efectos
  • Esteroides
  • Trastornos
  • Tratamiento
Neuroesteroides y blancos farmacológicos. Parte 2 - Dra. Estela Carranza Vélez

Dra. Estela

Dra. Estela Carranza Vélez Bibliografía • Barbaccia ML, Affricano D, Purdy RH, Maciocco E, Spiga F, Biggio G (2001).” Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat”. Neuropsychopharmacology 25: 489–497. • Baulieu, E.E., 1997. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog. Horm. Res. 52, 1–32. • Barron AM, Garcia-Segura LM, Caruso D, Jayaraman A, Lee JW, Melcangi RC, Pike CJ. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer’s disease. J Neurosci 2013; 33: 8891– 8897. • Darnaudery M, Pallares M, Piazza PV, Le Moal M, Mayo W. The neurosteroid pregnenolone sulfate infused into the medial septum nucleus increases hippocampal acetylcholine and spatial memory in rats. Brain Res 2002;951 (2):237–42. • Danovich L, Leo V, Svetlana L, Michal L ,Shuster V, Weizman A, Gavish M, “The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheraltype benzodiazepine receptor, and steroid production” European Neuropsychopharmacology (2008) 18, 24– 33. • Flood JF, Morley JE, Roberts E. (1992) Memoryenhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci; 89(5):1567–71. • Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 96:13512–13517. • Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry 1998; 44:865-87. • Kapur, S., Seeman, P., 2001. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158, 360–369. • Kapur, S., Zipursky, R.B., Remington, G., 1999. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156, 286– 293. • Kostakis E, Smith C, Jang MK, Martin SC, Richards KG, Russek SJ. (2013). The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N- methyl-D-aspartate receptors to the cell surface via a noncanonical G-protein and Ca2+-dependent mechanism. Mol Pharmacol; 84:26. • Li F, Liu J, Valls L, Hiser C, Ferguson-Miller S. Identification of a key cholesterol binding enhancement motif in translocator protein 18 kDa .Biochemistry 2015; 54: 1441–1443. • Lisman JE, Coyle, Robert . Green, Daniel C. Javitt Francine M. Benes, Stephan Heckers, and Anthony A. Grace, “Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia” Trends Neurosci. 2008 May ; 31(5): 234– 242. • Luszczki JJ (2009) Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 61:197–216. • Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL (2000) Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry 47:1000–1004. • Marx CE, Shampine LJ, Duncan GE, VanDoren MJ, Grobin AC, Massing MW, Madison RD, Bradford DW, Butterfield MI, Lieberman JA, Morrow AL (2006a) Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacol Biochem Behav 84: 598–608. • Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA (2006c) Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 31:1249–1263. • Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, Lieberman JA (2006e) The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer’s disease. Biol Psychiatry 60:1287–1294. • Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL (2003) Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28:1–13. • Marx CE, Yuan P, Kilts JD, Madison RD, Shampine LJ, Manji H (2008) Neuroactive steroids, mood stabilizers, and neuroplasticity: alterations following lithium and changes in Bcl-2 knockout mice. Int J Neuropsychopharmacol 11:547–552. • Marx CE, DuncanGE, Gilmore JH, LiebermanJA, Morrow AL(2000). Olanzapine increases allopregnanolone in the rat cerebral cortex. Biological psychiatry 47: 1000-1004. • Meltzer HY, McGurk SR. “The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia”. Schizophr Bull. 1999;25(2):233-55. Review. • Motzo C, Porceddu ML, Maira G, Flore G, Concas A, Dazzi L et al (1996). Inhibition of basal and stressinduced dopamine release in the cerebral cortex and nucleus accumbens of freely moving rats by the neurosteroid allopregnanolone. J Psychopharmacol 10: 266– 272. • Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general. • Papadopoulos V, Lecanu L. “Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma”. Exp Neurol 2009; 219: 53–57. • Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses inactive on 5-HT reuptake. Psychopharmacology 2006; 186:362–372. • Patchev VK, Shoaib M, Holsboer F, Almeida OF (1994) The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 62:265–271. • Patchev VK, Hassan AHS, Holsboer F, Almeida OFX (1996). The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 15: 533–540. • Porcu P, Barron AM, Frye CA, Walf AA, Yang SY, He XY, Morrow AL, Panzica GC, Melcangi RC. (2016).Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research. J Neuroendocrinol. Feb; 28(2):12351. • Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9: 971–988. • Rupprecht R, Rammes G, Eser D, Baghai TC, Schule C, Nothdurfter C, Troxler T, Gentsch C, Kalkman HO, Chaperon F, Uzunov V, McAllister KH, Bertaina- Anglade V, La Rochelle CD, Tuerck D, Floesser A, Kiese B, Schumacher M, Landgraf R, Holsboer F, Kucher K. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009; 325: 490–493. • Schule, C., Eser, D., Baghai, T.C., Nothdurfter, C., Kessler, J.S., Rupprecht, R., 2011. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 191, 55– 77. • Schule, C., Romeo, E., Uzunov, D.P., Eser, D., di Michele, F., Baghai, T.C., Pasini, A., Schwarz, M., Kempter, H., Rupprecht, R., 2006b. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol. Psychiatry 11, 261–272. • Schule C, Nothdurfter C, Rupprecht R. “The role of allopregnanolone in depression and anxiety”. Prog Neurobiol 2014; 113: 79–87. • Serra, M., Pisu, M.G., Littera, M., Papi, G., Sanna, E., Tuveri, F., Usala, L., Purdy, R.H., Biggio, G., 2000. Social isolation-induced decreases in both the abundance of neuroactive steroids and GABA(A) receptor function in rat brain. J. Neurochem. 75, 732–740. • Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002;26(5):583–9. • Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., Rush, A.J., 1999. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am. J. Psychiatry 156, 1164– 1169. • Tu LN, Morohaku K, Manna PR, Pelton SH, Butler WR, Stocco DM, Selvaraj V. Peripheral benzodiazepine receptor/translocator protein globalknock-out mice are viable with no effects on steroid hormone biosynthesis. J Biol Chem 2014; 289: 27444–27454. • Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95: 3239–3244. • Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci USA 1996;93:12599–12604. • Vallée M, Shen W, Heinrichs SC, Zorumski CF, Covey DF, Koob GF, Purdy RH (2001) Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats. Eur J Neurosci 14:2003–2010. • Vallée M, Neurosterids and potential therapeutics: Focus on pregnenolone. J. Steroid Biochem. Mol.Biol. (2015). • Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P.Tracking neuroinflammation in Alzheimer’s disease: the role of positrón emission tomography imaging. J Neuroinflammation 2014; 11: 120. 30 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015